13 Best Multibagger Stocks to Invest in Now

6. aTyr Pharma, Inc. (NASDAQ:ATYR)

Upside Potential:           485.17%

aTyr Pharma, Inc. (NASDAQ:ATYR) stands as a pioneering biotherapeutics company dedicated to discovering and developing innovative medicines targeting novel immunological pathways. Established in 2005, aTyr Pharma has carved out a niche in addressing the critical needs of patients suffering from interstitial lung diseases (ILDs), a group of disorders characterized by progressive scarring of lung tissues. Among its promising initiatives, the company’s lead therapeutic candidate, Efzofitimod, has emerged as a beacon of hope. Efzofitimod, a selective modulator of neuropilin-2 (NRP2), holds the potential to transform the treatment landscape for ILDs. Currently undergoing Phase III clinical trials, as well as Phase 1b/2a trials, Efzofitimod is designed to reduce inflammation and improve lung function, offering a possibility of reducing or even eliminating the need for corticosteroids, a significant advancement for patients who endure long-term side effects from these standard therapies.

The company’s commitment to advancing Efzofitimod has been bolstered by its strategic partnership with Kyorin Pharmaceutical Co., Ltd. This collaboration focuses on Efzofitimod’s development and commercialization in Japan, enabling aTyr Pharma to leverage Kyorin’s established presence and resources within the Japanese market while simultaneously concentrating its efforts on operations in the United States. Such global partnerships underscore aTyr Pharma’s forward-thinking approach to expanding its reach and ensuring the accessibility of its groundbreaking treatments.

In addition to its clinical endeavors, aTyr Pharma, Inc. (NASDAQ:ATYR) has a robust cash position of $88 million that provides a solid foundation for continued innovation and expansion. Analysts are optimistic about the stock, with 63% recommending it as a “Strong Buy” and the remainder holding a “Buy” position. Reflecting this confidence, the consensus amongst analysts pegs the average share price at $18.55 over the next twelve months, marking an upside potential of 485.17%.